Which hedge funds own TARS? TARSUS PHARMACEUTICALS INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
7 of the hedge funds tracked by WhaleCreep disclosed a position in TARS (TARSUS PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $157.8m in total. The largest holder by portfolio weight is Millennium Management at 0.1% of its book. 2 managers opened a new position this quarter: Brevan Howard Capital Management, Tudor Investment. 1 exited: Point72 Asset Management LP.
7tracked managers holding
2opened this quarter
1exited this quarter
Which hedge funds hold TARS? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Millennium Management | Q2 2026 | 0.1% | $89.8m | 1,427,124 | 153% | added |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $44.7m | 710,559 | -10% | reduced |
| Woodline Partners | Q2 2026 | 0.0% | $6.3m | 100,443 | 0% | held |
| Citadel Advisors | Q2 2026 | 0.0% | $15.2m | 241,737 | 47% | added |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $503.1k | 7,993 | – | new |
| Tudor Investment | Q2 2026 | 0.0% | $600.5k | 9,541 | – | new |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $585.3k | 9,300 | -87% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Point72 Asset Management LP | 0.4% | $15.9m |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| Caxton Associates | Q4 2024 | 0.0% |
How has hedge fund ownership of TARS changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 7 | $157.8m |
| Q1 2026 | 6 | $134.7m |
| Q4 2025 | 4 | $18.4m |
| Q3 2025 | 2 | $8.4m |
| Q2 2025 | 1 | $4.1m |
| Q1 2025 | 1 | $5.1m |
| Q4 2024 | 3 | $7.7m |
| Q3 2024 | 1 | $2.4m |
| Q1 2024 | 1 | $679.6k |
| Q4 2023 | 1 | $396.4k |
| Q3 2023 | 3 | $4.6m |
| Q2 2023 | 1 | $2.1m |
| Q1 2023 | 2 | $3.7m |
| Q4 2022 | 2 | $5.1m |
| Q3 2022 | 2 | $6.1m |
| Q2 2022 | 2 | $3.8m |
Counts every tracked manager that disclosed TARS in that quarter's filing, including managers that have since stopped filing.